The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials

[1]  Clifford R. Jack,et al.  The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable , 2018, Alzheimer's & Dementia.

[2]  Michael W. Lutz,et al.  Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA-AA Research Framework , 2018, Alzheimer's & Dementia.

[3]  E. Masliah,et al.  NIA commentary on the NIA-AA Research Framework: Towards a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[4]  J. Cummings,et al.  Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future , 2018, Journal of Alzheimer's disease : JAD.

[5]  Henrik Zetterberg,et al.  Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease , 2018, Neurology.

[6]  Lei Yu,et al.  Person‐specific contribution of neuropathologies to cognitive loss in old age , 2018, Annals of neurology.

[7]  J. Sepulcre,et al.  In vivo staging of regional amyloid deposition , 2017, Neurology.

[8]  D. Na,et al.  Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease , 2017, Neurobiology of Aging.

[9]  J. Cummings.  Disease modification and Neuroprotection in neurodegenerative disorders , 2017, Translational Neurodegeneration.

[10]  James B. Rowe,et al.  PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers , 2017, Journal of Alzheimer's disease : JAD.

[11]  Simon Cervenka,et al.  In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings , 2017, Ageing Research Reviews.

[12]  M. Weiner,et al.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons , 2017, JAMA.

[13]  M. Mintun,et al.  Association between tau deposition and antecedent amyloid-&bgr; accumulation rates in normal and early symptomatic individuals , 2017, Brain : a journal of neurology.

[14]  D. Bennett,et al.  Outcomes after diagnosis of mild cognitive impairment in a large autopsy series , 2017, Annals of neurology.

[15]  Luca Passamonti,et al.  18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy , 2017, Brain : a journal of neurology.

[16]  M. Mintun,et al.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition , 2017, Brain : a journal of neurology.

[17]  Michael Tanen,et al.  The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients , 2016, Science Translational Medicine.

[18]  D. Bennett,et al.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. , 2016, Brain : a journal of neurology.

[19]  A. Fagan,et al.  Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. , 2016, JAMA neurology.

[20]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[21]  Yi Su,et al.  The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. , 2016, Brain : a journal of neurology.

[22]  Hanna Cho,et al.  Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.

[23]  Yi Su,et al.  Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease , 2016, Science Translational Medicine.

[24]  Min Su Kang,et al.  Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease , 2016, Molecular Psychiatry.

[25]  J. Sevigny,et al.  Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial , 2016, Alzheimer disease and associated disorders.

[26]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[27]  Nick C Fox,et al.  Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[28]  Frederik Barkhof,et al.  Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease , 2015, Neurobiology of Aging.

[29]  A. Fagan,et al.  Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. , 2015, JAMA neurology.

[30]  W. Klein,et al.  Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis , 2015, Acta Neuropathologica.

[31]  J. Clarimón,et al.  Cerebrospinal fluid β‐amyloid and phospho‐tau biomarker interactions affecting brain structure in preclinical Alzheimer disease , 2014, Annals of neurology.

[32]  N. Laskaris,et al.  Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease , 2014, Alzheimer's & Dementia.

[33]  E. Londos,et al.  Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies , 2013, International journal of geriatric psychiatry.

[34]  A. Wall,et al.  Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients. , 2013, Journal of Alzheimer's disease : JAD.

[35]  R. Kayed,et al.  Molecular mechanisms of amyloid oligomers toxicity. , 2012, Journal of Alzheimer's disease : JAD.

[36]  Olivier Colliot,et al.  CSF tau markers are correlated with hippocampal volume in Alzheimer's disease , 2012, Neurobiology of Aging.

[37]  R. Perry,et al.  Quantitative neurodegenerative pathology does not explain the degree of hippocampal atrophy on MRI in degenerative dementia , 2012, International journal of geriatric psychiatry.

[38]  C. Jack,et al.  Chronic divalproex sodium use and brain atrophy in Alzheimer disease , 2011, Neurology.

[39]  C. Jack,et al.  3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects , 2010, Neurobiology of Aging.

[40]  S. Leurgans,et al.  The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.

[41]  A. Drzezga,et al.  Brain Metabolic Correlates of Cerebrospinal Fluid Beta-Amyloid 42 and Tau in Alzheimer’s Disease , 2009, Dementia and Geriatric Cognitive Disorders.

[42]  Christine Van Broeckhoven,et al.  No association of CSF biomarkers with APOEε4, plaque and tangle burden in definite Alzheimer's disease , 2007 .

[43]  Ivo D Dinov,et al.  Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. , 2005, Archives of neurology.

[44]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[45]  Lei Wang,et al.  Correlations Between Antemortem Hippocampal Volume and Postmortem Neuropathology in AD Subjects , 2004, Alzheimer disease and associated disorders.

[46]  J. Tribble,et al.  Early Alzheimer’s Disease: Developing Drugs for Treatment (FDA Draft Guidance for Industry) , 2019 .

[47]  Clare E. Mackay,et al.  PET Tau and Amyloid-beta Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers (vol 60, pg 283, 2017) , 2018 .

[48]  C. Jack,et al.  Framework : Towards a Biological Definition of Alzheimer ’ s Disease 1 2 draft 9-19-17 3 4 5 , 2017 .

[49]  D. Ames,et al.  Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. , 2015, Journal of Alzheimer's disease : JAD.

[50]  P. Scheltens,et al.  Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[51]  J. Morris,et al.  Clinicopathologic study of Alzheimer's disease: Alzheimer mimics. , 2013, Journal of Alzheimer's disease : JAD.

[52]  Kewei Chen,et al.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.

[53]  Sebastiaan Engelborghs,et al.  No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. , 2007, Brain : a journal of neurology.

[54]  Sterling C. Johnson,et al.  Relationship of cognitive measures and gray and white matter in Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[55]  A W Toga,et al.  Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. , 2001, Neuropsychiatry, neuropsychology, and behavioral neurology.